Journal Mobile Options
Table of Contents
Vol. 16, No. 3, 1999
Issue release date: June 1999
Exp Clin Immunogenet 1999;16:125–130

Plasma α1,3-Fucosyltransferase Deficiency in Schizophrenia

Yazawa S. · Tanaka S. · Nishimura T. · Miyanaga K. · Kochibe N.
aJapan Immunoresearch Laboratories, Takasaki, bDepartment of Neuropsychiatry, Gunma University School of Medicine, and cDepartment of Biology, Faculty of Education, Gunma University, Maebashi, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Levels of plasma α1,3-fucosyltransferase (α1,3FT) were assayed in 44 patients with schizophrenia and in 50 healthy controls. Significantly reduced enzyme activities were observed in patients (p < 0.05) and 4 unrelated patients were found, for the first time in Japan, to be deficient in the enzyme activity. Two point mutations in the coding region of the FUT6 gene encoding plasma α1,3FT that were responsible for the inactivation of the enzyme activity were detected in those patients. Genotyping of the Le gene (FUT3) in these patients demonstrated that 2 of them were also FUT3 deficient and were grouped as Lewis– individuals whereas the rest were Lewis+.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Brinkman-Van der Linden ECM, Mollicone R, Oriol R, Larson G, Van den Eijinden DH, Van Dijk W: A missense mutation in the FUT6 gene results in total absence of α3-fucosylation of human α1-acid glycoprotein. J Biol Chem 1996;271:14492–14495.
  2. Yazawa S, Madiyalakan R, Izawa H, Asao T, Furukawa K, Matta KL: Cancer-associated elevation of α(1→3)-L-fucosyltransferase activity in human serum. Cancer 1988;62:516–520.
  3. Greenwell P, Johnson PH, Edwards JM, Reed RM, Moores PP, Bird A, Graham HA, Watkins WM: Association of the human Lewis blood group Le(a–b–c–d–) with the failure of expression of alpha-3-L-fucosyltransferase. Rev Fr Transfus Immunohematol 1986;29:233–249.

    External Resources

  4. Caillard T, Le Pendu J, Ventura M, Mada M, Rault G, Mannoni R, Orial R: Failure of expression of alpha-3-L-fucosyltransferase in human serum is coincident in the kidney but not on leucocytes. Exp Clin Immunogenet 1988;5:15–23.

    External Resources

  5. Mollicone R, Reguigne I, Fletcher A, Aziz A, Rustam M, Weston BW, Kelly RJ, Lowe JB, Oriol R: Molecular basis for plasma α(1,3)fucosyltransferase gene deficiency (FUT6). J Biol Chem 1994;269:12662–12671.

    External Resources

  6. Varma R, Hoshino AY, Vercellotti JR: Serum glycoproteins in schizophrenia. Carbohydr Res 1980;82:343–351.
  7. Brunngraber EG, Davis LG, Rieser C, Reddy MV: Urinary glycoconjugates in schizophrenic patients. Biol Psychiat 1981;16:741–751.
  8. Maguire TM, Thakore J, Dinan TG, Hopwood S, Breen KC: Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA axis function. Biol Psychiatry 1997;41:1131–1136.
  9. Mellshop GW, Koadlow L, Wittingham S: Absence of rheumatoid arthritis in schizophrenia. Aust N Z J Med 1974;4:247–252.

    External Resources

  10. Eaton WW, Hayward C, Rana R: Schizophrenia and rheumatoid arthritis: A review. Schizophr Res 1992;6:181–192.
  11. Yazawa S, Nakamura J, Asao T, Nagamachi Y, Sagi M, Matta KL, Tachikawa T, Akamatsu M: Aberrant α1→2fucosyltransferase found in human colorectal carcinoma involved in the accumulation of Leb and Y antigens in colorectal tumors. Jpn J Cancer Res 1993;84:989–995.
  12. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  13. Borsig L, Katopodis AG, Bowen BR, Berger EG: Trafficking and localization studies of recombinant α1,3-fucosyltransferase VI stably expressed in CHO cells. Glycobiology 1998;8:259–268.
  14. Nakamura J, Mogi A, Asao T, Nagamachi Y, Yazawa S: Evidence that the aberrant α1→2fucosyltransferase found in colorectal carcinoma may be encoded by Fuc-TIII (Le) gene. Anticancer Res 1997;17:4563–4570.

    External Resources

  15. Yazawa S, Nishihara S, Iwasaki H, Asao T, Nagamachi Y, Matta KL, Narimatsu H: Genetic and enzymatic evidence for Lewis enzyme expression in Lewis-negative cancer patients. Cancer Res 1995;55:1473–1478.
  16. Nishihara S, Narimatsu H, Iwasaki H, Yazawa S, Akamatsu S, Ando T, Seno T, Narimatsu I: Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem 1994;269:29271–29278.

    External Resources

  17. Yazawa S, Oh-Kawara H, Nakajima T, Hosomi O, Akamatsu S, Kishi K: Histo-blood group Lewis genotyping from human hairs and blood. Jpn J Hum Genet 1996;41:177–188.

    External Resources

  18. Reguigne-Arnould I, Couillin P, Mollicone R, Faure S, Fletcher A, Kelly RJ, Low JB, Oriol R: Relative positions of two clusters of human α-L-fucosyltransferases in 19q (FUT1-FUT2) and 19p (FUT6-FUT3-FUT5) within the microsatellite genetic map of chromosome 19. Cytogenet Cell Genet 1995;71:158–162.
  19. Larson G, Börjeson C, Elmgren A, Kernholt A, Henry S, Fletcher A, Azia A, Mollicone R, Oriol R: Identification of a new plasma α(1,3)fucosyltransferase (FUT6) allele requires an extended genotyping strategy. Vox Sang 1996;71:233–241.
  20. Chodirker BN, Chudley AE, Ray M, Wickstrom DE, Riordan DL: Fragile 19p13 in a family with mental illness. Clin Genet 1987;31:1–6.
  21. Watkins WM: Biosynthesis 5. Molecular basis of antigenic specificity in the ABO, H and Lewis blood-group systems; in Montreuil J, Vliegenthart JFG, Schachter H (eds): Glycoproteins. Amsterdam, Elsevier Science, 1995, 29a, pp 313–390.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50